登录 |  注册 |  忘记密码 |  公司首页
简体   繁體   English
首页 > 癌症(英文版) >Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma

For decades, the selection of chemotherapeutic regimens for the treatment of recurrent or metastatic nasopharyn-geal carcinoma has been mainly empirical. To our knowledge, there is no phase 3 trial that has been conducted to determine the optimal treatment for these patients before our publication. Recently, we published an article inThe Lancet entitled “Gemcitabine plus cisplatin versus lfuorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.” The results of our study indicate that gemcitabine plus cisplatin could improve the survival of patients with recurrent or metastatic nasopharyngeal carcinoma com-pared with conventional lfuorouracil plus cisplatin.

作 者 Shaodong Hong(Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, P. R. China);Li Zhang(Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, P. R. China);
刊 名 癌症(英文版)  2016年35卷12期 645-646页  美国《化学文摘》(Chemical Abstracts)收录中国科技论文统计源期刊(中国科技核心期刊)收录
关键词 Metastasis Nasopharyngeal carcinoma Chemotherapy
DOI号 10.1186/s40880-016-0163-6

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他相关网站。

北京万方数据股份有限公司

万方数据电子出版社

关于我们  |   联系我们  |   网站地图  |   主要产品  |   主要服务

使用帮助  |   服务承诺  |   诚聘英才  |   友情链接  |   知识产权

客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

客服邮箱:yiyao@wanfangdata.com.cn

充值卡购卡热线:400-667-1808

互联网出版许可证 新出网证(京)字042号

互联网药品信息服务资格证书号:(京)-经营性-2011-0017

信息网络传播视听节目许可证

京公网安备11010802020237号

京ICP证010071号